LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2-advanced or metastatic breast cancer

被引：0
|
作者：
Hu, Xichun
Wang, Biyun
Wang, Shusen
Tong, Zhongsheng
Sun, Tao
Li, Wei
Song, Lihua
Yan, Xi
Cheng, Ying
Qiu, Fuming
Wang, Xinshuai
Xie, Weimin
Zhao, Bing
Liu, Xinlan
Hu, Changlu
Lai, Guie
Pang, Jinke
Li, Tong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[4] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[5] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[6] First Hosp Jilin Univ, Changchun, Peoples R China
[7] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Jilin Canc Hosp, Changchun, Peoples R China
[10] Zhejiang Univ, Sch Med, Affliated Hosp 2, Hangzhou, Peoples R China
[11] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[12] Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China
[13] Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China
[14] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China
[15] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[16] Jiangxi Med Coll, Affiliated Hosp 1, Ganzhou, Peoples R China
[17] Genor Biopharma Co Ltd, Shanghai, Peoples R China
[18] Genor Biopharma Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [2] Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial
    O'Shaughnessy, Joyce
    Petrakova, Katarina
    Sonke, Gabe S.
    Conte, Pierfranco
    Arteaga, Carlos L.
    Cameron, David A.
    Hart, Lowell L.
    Villanueva, Cristian
    Jakobsen, Erik
    Beck, Joseph T.
    Lindquist, Deborah
    Souami, Farida
    Mondal, Shoubhik
    Germa, Caroline
    Hortobagyi, Gabriel N.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 127 - 134
  • [3] Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Mistry, Rohit
    May, Jessica R.
    Suri, Gaurav
    Young, Kate
    Brixner, Diana
    Oderda, Gary
    Biskupiak, Joseph
    Tang, Derek
    Bhattacharyya, Subrata
    Mishra, Dinesh
    Bhattacharyya, Devarshi
    Dalal, Anand A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (06): : 514 - +
  • [4] Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
    Guarneri, Valentina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1549 - 1557
  • [5] Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2-advanced breast cancer
    Jhaveri, Komal
    O'Shaughnessy, Joyce
    Fasching, Peter A.
    Tolaney, Sara M.
    Yardley, Denise A.
    Sharma, Vikash Kumar
    Biswas, Chandroday
    Thuerigen, Astrid
    Pathak, Purnima
    Rugo, Hope S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [6] Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2-Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
    Fein, Luis
    Lazaretti, Nicolas
    Chuken, Yamil Lopez
    Benfield, J. Rogelio Gonzalez Ramirez
    Mano, Max S. S.
    Lobaton, Jose
    Korbenfeld, Ernesto
    Damian, Fernanda
    Lu, Dongrui R. R.
    Mori, Ave
    Patyna, Shem J. J.
    Franco, Sandra
    CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 699 - 706
  • [7] Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer
    Fasching, Peter A.
    Delea, Thomas E.
    Lu, Yen-Shen
    De Boer, Richard
    Hurvitz, Sara A.
    Moynahan, Aaron
    Chandiwana, David
    Lanoue, Brad
    Hu, Huilin
    Thuerigen, Astrid
    O'Shaughnessy, Joyce
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8179 - 8189
  • [8] Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
    Joyce O’Shaughnessy
    Katarina Petrakova
    Gabe S. Sonke
    Pierfranco Conte
    Carlos L. Arteaga
    David A. Cameron
    Lowell L. Hart
    Cristian Villanueva
    Erik Jakobsen
    Joseph T. Beck
    Deborah Lindquist
    Farida Souami
    Shoubhik Mondal
    Caroline Germa
    Gabriel N. Hortobagyi
    Breast Cancer Research and Treatment, 2018, 168 : 127 - 134
  • [9] Ribociclib plus letrozole vs. letrozole alone in HR+/HER2L advanced breast cancer: a systematic review and metaanalysis
    Sabran, M. Z.
    Hutauruk, C. E. O. L.
    Budianto, C. J.
    Purushotama, N. B. S. A.
    Lee, J. V.
    Wibisono, M. G.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1332 - S1332
  • [10] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345